Jeffrey Ciavarri

Jeff received his Ph.D. in synthetic organic chemistry from the University of Notre Dame followed by post-doctoral work at the University of Pennsylvania under the direction of Prof. Amos B. Smith III. Prior to joining Mitobridge in 2020, he held positions as a medicinal chemist at Millennium Pharmaceuticals, Schering-Plough and Takeda Pharmaceuticals within the Inflammation, Oncology and Immuno-oncology disease areas. A significant amount of his research in small-molecule drug discovery has focused on targeting the ubiquitin-proteasome system to find new medicines for the treatment of cancer.